Jump to content

Adverum Biotechnologies

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Doc James (talk | contribs) at 06:35, 15 October 2016. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Avalanche Biotechnologies is a publicly traded (NASDAQ:AAVL)[1] biotechnology company in the NASDAQ Biotechnology Index that is worth 245 million that is dedicated to diseases of the eye.[2] This includes macular degeneration,[3] retinal vein occlusion,[4] diabetic macular edema,[5] and others.[6]

References

  1. ^ "Avalanche Biotechnologies, Inc (AAVL)". NASDAQ.com. Retrieved 4 January 2016.
  2. ^ "Avalanche Biotechnologies Announces Leadership Transition". www.reuters.com. Retrieved 4 January 2016.
  3. ^ "Is Avalanche Biotechnologies A Good Buy Now After Phase 2 Results For Its Wet AMD Drug? - Avalanche Biotechnologies (NASDAQ:AAVL)". Seeking Alpha. Retrieved 4 January 2016.
  4. ^ Burger, Danielle. "Avalanche Drops as Gene Therapy Data Miss High Expectations". Bloomberg.com.
  5. ^ "Update on the latest in business:". WTOP. Tegna Media. Retrieved 4 January 2016.
  6. ^ Burger, Danielle. "Avalanche drops eye drug trial, takes it back to lab". CNBC.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Adverum_Biotechnologies&oldid=744438758"